Author | Konstantin Linnik

Articles

The Myriad Ruling: Six Points Every Biotech CEO Must Consider

Pharmaceutical Executive

Last week, the US Supreme Court issued a long-awaited decision in Myriad Genetics, which sent shockwaves through the very foundation of the biotech industry